MEDCL Stock Overview
A pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
MedinCell S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €18.10 |
52 Week High | €18.74 |
52 Week Low | €5.25 |
Beta | 1.17 |
11 Month Change | 13.55% |
3 Month Change | 21.15% |
1 Year Change | 172.59% |
33 Year Change | 96.74% |
5 Year Change | 162.32% |
Change since IPO | 146.26% |
Recent News & Updates
Recent updates
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Shareholder Returns
MEDCL | FR Pharmaceuticals | FR Market | |
---|---|---|---|
7D | 3.2% | 1.1% | 1.6% |
1Y | 172.6% | -0.1% | 1.3% |
Return vs Industry: MEDCL exceeded the French Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: MEDCL exceeded the French Market which returned 1.3% over the past year.
Price Volatility
MEDCL volatility | |
---|---|
MEDCL Average Weekly Movement | 6.1% |
Pharmaceuticals Industry Average Movement | 4.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in FR Market | 9.8% |
10% least volatile stocks in FR Market | 2.6% |
Stable Share Price: MEDCL's share price has been volatile over the past 3 months.
Volatility Over Time: MEDCL's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 134 | Christophe Douat | www.medincell.com |
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
MedinCell S.A. Fundamentals Summary
MEDCL fundamental statistics | |
---|---|
Market cap | €526.49m |
Earnings (TTM) | -€25.04m |
Revenue (TTM) | €11.95m |
44.1x
P/S Ratio-21.0x
P/E RatioIs MEDCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MEDCL income statement (TTM) | |
---|---|
Revenue | €11.95m |
Cost of Revenue | €0 |
Gross Profit | €11.95m |
Other Expenses | €36.98m |
Earnings | -€25.04m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Dec 03, 2024
Earnings per share (EPS) | -0.86 |
Gross Margin | 100.00% |
Net Profit Margin | -209.61% |
Debt/Equity Ratio | -151.4% |
How did MEDCL perform over the long term?
See historical performance and comparison